Repository logo
 
Publication

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

2022-05-26Journal article Open access
Simple item page
dc.contributor.authorKissling, Esther
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorMazagatos, Clara
dc.contributor.authorWilliam, Naoma
dc.contributor.authorVilcu, Ana-Maria
dc.contributor.authorKooijman, Marjolein N.
dc.contributor.authorIlić, Maja
dc.contributor.authorDomegan, Lisa
dc.contributor.authorMachado, Ausenda
dc.contributor.authorde Lusignan, Simon
dc.contributor.authorLazar, Mihaela
dc.contributor.authorMeijer, Adam
dc.contributor.authorBrytting, Mia
dc.contributor.authorCasado, Itziar
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorMurray, Josephine-L.K.
dc.contributor.authorBehillil, Sylvie
dc.contributor.authorde Gier, Brechje
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorO’Donnell, Joan
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorTsang, Ruby
dc.contributor.authorTimnea, Olivia
dc.contributor.authorde Lange, Marit
dc.contributor.authorRiess, Maximilian
dc.contributor.authorCastilla, Jesús
dc.contributor.authorPozo, Francisco
dc.contributor.authorHamilton, Mark
dc.contributor.authorFalchi, Alessandra
dc.contributor.authorKnol, Mirjam J.
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorDunford, Linda
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorCogdale, Jade
dc.contributor.authorCherciu, Carmen
dc.contributor.authorJansen, Tessa
dc.contributor.authorEnkirch, Theresa
dc.contributor.authorBasile, Luca
dc.contributor.authorConnell, Jeff
dc.contributor.authorGómez, Verónica
dc.contributor.authorSandonis Martín, Virginia
dc.contributor.authorBacci, Sabrina
dc.contributor.authorRose, Angela M.C.
dc.contributor.authorPastore Celentano, Lucia
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE-COVID-19 and ECDC primary care study teams
dc.date.accessioned2024-01-18T11:36:42Z
dc.date.available2024-01-18T11:36:42Z
dc.date.issued2022-05-26
dc.descriptionMulticentre Studypt_PT
dc.descriptionI-MOVE-COVID-19 and ECDC primary care study team (in addition to authors above): Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon,, Caroline Guerrisi,, Titouan Launay,, Shirley Masse,, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O’Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairspt_PT
dc.description.abstractIntroduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.pt_PT
dc.description.sponsorshipThis project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2022 May;27(21):2101104. doi: 10.2807/1560-7917.ES.2022.27.21.2101104pt_PT
dc.identifier.doi10.2807/1560-7917.ES.2022.27.21.2101104pt_PT
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/8920
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relationMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.21.2101104pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectDelta Variantpt_PT
dc.subjectMulticentre Studypt_PT
dc.subjectTest-negative Designpt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectEuropept_PT
dc.subjectVacinapt_PT
dc.subjectEfetividadept_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.subjectCuidados de Saúdept_PT
dc.subjectEuropapt_PT
dc.subjectI-MOVEpt_PT
dc.titleEffectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleMultidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/101003673/EU
oaire.citation.issue21pt_PT
oaire.citation.startPage2101104pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume27pt_PT
oaire.fundingStreamH2020
person.familyNameMachado
person.familyNameRodrigues
person.familyNameGuiomar
person.familyNameGOMEZ TEIXEIRA PINTO
person.familyNameKislaya
person.givenNameAusenda
person.givenNameAna Paula
person.givenNameRaquel
person.givenNameVERÓNICA DEL PILAR
person.givenNameIrina
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.ciencia-idFA1B-D68F-2611
person.identifier.ciencia-idA815-4295-F91D
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0003-2264-4723
person.identifier.orcid0000-0002-4563-6315
person.identifier.orcid0000-0003-0485-0005
person.identifier.orcid0000-0001-5772-2416
person.identifier.scopus-author-id56442728800
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.embargofctAcesso de acordo com a política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationc23c6d96-e605-424f-abbb-64d783c73939
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublicationeae04cda-2c73-437b-8666-6593d03aa34d
relation.isAuthorOfPublicationcf6a6914-1de2-4c2a-96b1-9d617ca28a15
relation.isAuthorOfPublication.latestForDiscoveryc23c6d96-e605-424f-abbb-64d783c73939
relation.isProjectOfPublication7403e02d-5360-418c-8e37-687c3a1349f8
relation.isProjectOfPublication.latestForDiscovery7403e02d-5360-418c-8e37-687c3a1349f8

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effectiveness of complete primary vaccination against COVID-19_IMOVE COVID_july august 2021.pdf
Size:
627.55 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais